## **60.Lipid disorders**

Abstract No.	First Name	Last Name	Program No.	Session	Session Title	Date	Time	Order	Room	Abstract Title
10110	Masahiro	Suzuki	OE21-3	Oral Presentation21	Lipid Disorders	March 12 (Sat)	10:30-12:00	3	Room 24 (504+505, 5F, Kobe International Conference Center)	Serum Amyloid A-low-density-lipoprotein Complex and Mortality in Patients with Suspected or Known Coronary Artery Disease: The ANOX Study
10145	Ryosuke	Fujiwara	OE21-7	Oral Presentation21	Lipid Disorders	March 12 (Sat)	10:30-12:00	7	Room 24 (504+505, 5F, Kobe International Conference Center)	Independent Association of Achilles Tendon Thickness with Coronary Lesion Severity in Premature Coronary Artery Disease Patients without Familial Hypercholesterolemia
10376	Sho	Nakao	PJ18-2	Poster Session (Japanese)18	Lipid Disorders/Preventive Medicine	March 11 (Fri)	15:05-15:55	2	Poster Session Room 2 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	In-hospital protocol of intensive lipid-lowering therapy to decrease the mortality in patients with acute coronary syndrome
10483	Tomoaki	Okada	MPJ01-1		Lipid Disorders/Metabolic Syndrome/SAS	March 11 (Fri)	08:00-09:30	1	Mini Oral Session Room 6 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	Efficacy of Early Initiation of Evolocumab on Lipoprotein (a) in Patients with Acute Myocardial Infarction
10630	Eri	Shimada	CRRP01-4	症例報告セッション(学生・初期研修医 ポスター)01	学生・初期研修医1	March 11 (Fri)	15:05-15:55	4	Poster Session Room 2 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	A Case of Adult Sitosterolemia Diagnosed in the Wake of a Breastfed Hypercholesterolemia in Her Daughter
10635	Shun	Murai	PJ18-1	Poster Session (Japanese)18	Lipid Disorders/Preventive Medicine	March 11 (Fri)	15:05-15:55	1	Poster Session Room 2 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	Is High Value of Serum LDL-cholesterol A Foe in Elderly Patients without Heart Disease?
10777	Shinji	Takahashi	PJ18-3	Poster Session (Japanese)18	Lipid Disorders/Preventive Medicine	March 11 (Fri)	15:05-15:55	3	Poster Session Room 2 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	The relationship of a high triglyceride level and vulnerable plaque in patients treated with statins for primary prevention
10977	Yasunori	Suematsu	OE21-8	Oral Presentation21	Lipid Disorders	March 12 (Sat)	10:30-12:00	8	Room 24 (504+505, 5F, Kobe International Conference Center)	The Effect of Pegylated Fukuoka Apolipoprotein A1 Mimetic Peptide for Cholesterol Efflux Capacity
10990	Hideki	Okada	MPJ01-4		Lipid Disorders/Metabolic Syndrome/SAS	March 11 (Fri)	08:00-09:30	4	THE HAILING & BUILDING KONE INTERNATIONAL	The lipid profile characteristics of the diabetic patients: From the analysis of the detailed lipid profile data
11013	Takao	Kishinoue	PJ39-7	Poster Session (Japanese)39	Heart Failure (Pathophysiology 3)	March 13 (Sun)	09:35-10:25	7	Poster Session Room 1 (Convention Hall, 1F, Hall No.2 Building, Kobe International Exhibition Hall)	Examination of clinical characteristics in congestive heart failure patients with atrial fibrillation.
11109	Tatsuaki	Murakami	MPJ01-3		Lipid Disorders/Metabolic Syndrome/SAS	March 11 (Fri)	08:00-09:30	3	Mini Oral Session Room 6 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	Pemafibrate Provides Multiple Antiatherothrombotic Effects for Patients with Dyslipidemia Receiving Statin
11229	Nobuko	Kojima	OE21-1	Oral Presentation21	Lipid Disorders	March 12 (Sat)	10:30-12:00	1	Room 24 (504+505, 5F, Kobe International Conference Center)	Determination of Pathogenicity in <i>ABCG5</i> and <i>ABCG8</i> among Japanese Dyslipidemic Patients.
11323	Kan	Yamagami	OE21-5	Oral Presentation21	Lipid Disorders	March 12 (Sat)	10:30-12:00	5	Room 24 (504+505, 5F, Kobe International Conference Center)	Investigation of Genetic Backgrounds Contributing to Lp(a) levels among Japanese Population
11330	Tatsuya	Tabata	OE21-2	Oral Presentation21	Lipid Disorders	March 12 (Sat)	10:30-12:00	2	Room 24 (504+505, 5F, Kobe International Conference Center)	Impact of Lipid Management at Chronic Phase on Prognosis of Patients underwent Percutaneous Coronary Intervention
11649	Masahiro	Uehara	CRDP04-6	症例報告セッション(医 師 ポスター) <b>04</b>	ACS/Vascular Disease	March 13 (Sun)	09:35-10:25	6	Poster Session Room 2 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	A Case of Hypertriglyceridemia due to GPIHBP1 Autoantibody Syndrome.
11830	Ken	Nishikawa	OE21-4	Oral Presentation21	Lipid Disorders	March 12 (Sat)	10:30-12:00	4	Room 24 (504+505, 5F, Kobe International Conference Center)	Effect of Statins in Patients with Peripheral Arterial Disease with LDL Cholesterol Less than 120 mg/dl; from I-PAD registry
12084	Katsunao	Tanaka	MPJ01-2	Moderated Poster Session (Japanese)01	Lipid Disorders/Metabolic Syndrome/SAS	March 11 (Fri)	08:00-09:30	2	Mini Oral Session Room 6 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	Examination of the combination therapy of pemafibrate and statins to serum lipid and hepatic lipid contents in <i>Ldlr<sup>+/-</sup></i> mice(FH model)
12181	Tomko	Inoue	MPJ01-5		Lipid Disorders/Metabolic Syndrome/SAS	March 11 (Fri)	08:00-09:30	5	Mini Oral Session Room 6 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	Response to Statin Treatment as a Clue of Harboring Pathogenic Variants in Pediatric Familial Hypercholesterolemia
12198	Masaya	Sano	PJ18-7	Poster Session (Japanese)18	Lipid Disorders/Preventive Medicine	March 11 (Fri)	15:05-15:55	7	Poster Session Room 2 (Exhibiton Hall, 1F, Hall No.3 Building, Kobe International Exhibition Hall)	The Cut-Off Value of Baseline Lipoprotein(a) Concentration to Predict Clinical Outcomes of the Patients with AMI after Primary PCI